Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Daratumumab Activity Is Agnostic to Fc Gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Primary Refractory or Relapsed Systemic AL Amyloidosis

Lisa Xingguang Lee, MD, Katelynn Ho, Ping Zhou, PhD MD, Cindy Varga, MD BSc, Teresa Fogaren, NP, Denis Toskic, Adin Kugelmass, Raymond Comenzo, MD

Blood (2017) 130 (Supplement 1): 3164.

https://doi.org/10.1182/blood.V130.Suppl_1.3164.3164

Published: 2017

Journal Articles

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Heather Landau, MD, Hani Hassoun, MD, Adam D Cohen, MD, Alexander Lesokhin, MD, Christina Bello, Elizabeth Hoover, Elyn R Riedel, MD, Jennifer Ciminiello, RN, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD, Raymond Comenzo, MD

Blood (2009) 114 (22): 533.

https://doi.org/10.1182/blood.V114.22.533.533

Published: 2009

Journal Articles

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Hani Hassoun, MD, Heather Landau, MD, Chirag Surti, Nelly G. Adel, PharmD, Xiaoyu Jia, MS, Elyn R Riedel, MA, Bhutani Manisha, MD, Raymond Comenzo, MD, Alexander Lesokhin, MD, David J. Chung, MD, PhD, Jennifer Ciminiello, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD

Blood (2009) 114 (22): 1865.

https://doi.org/10.1182/blood.V114.22.1865.1865

Published: 2009

Journal Articles

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

James E. Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Elizabeth Hoover, Adam Cohen, MD, Stephen Nimer, MD, Raymond Comenzo, MD

Blood (2008) 112 (11): 3329.

https://doi.org/10.1182/blood.V112.11.3329.3329

Published: 2008

Journal Articles

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Hani Hassoun, MD, Brian T. Rafferty, MS, Carlos Flombaum, MD, Vivette D. D’Agati, MD, Virginia M. Klimek, MD, Adam Cohen, MD, Adam Boruchov, MD, Tarun Kewalramani, MD, Lilian Reich, MD, Heather Landau, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2007) 110 (11): 5113.

https://doi.org/10.1182/blood.V110.11.5113.5113

Published: 2007

Journal Articles

CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.

Adam Boruchov, MD, P. Zhou, MD, PhD, A. Olshen, PhD, C. Rankin, E. Bonvini, MD, S. Koenig, MD, PhD, M. Fleisher, PhD, R. Rose, S. McKenzie, Peter Maslak, MD, Suresh C. Jhanwar, PhD, James W. Young, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2006) 108 (11): 3489.

https://doi.org/10.1182/blood.V108.11.3489.3489

Published: 2006

Journal Articles

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Raymond Comenzo, MD, Hani Hassoun, MD, Lilian Reich, MD, Nancy Collins, PhD, Andre Nuta, Xiaoshe Chen, PhD, Ping Zhou, MD. PhD, Bradly Clark, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, David Wuest, MD, Stephen D. Nimer, MD

Blood (2006) 108 (11): 3087.

https://doi.org/10.1182/blood.V108.11.3087.3087

Published: 2006

Journal Articles

Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).

Neal Flomenberg, MD, Raymond Comenzo, MD, Karin Badel, Gary Calandra, MD

Blood (2006) 108 (11): 3381.

https://doi.org/10.1182/blood.V108.11.3381.3381

Published: 2006

Journal Articles

Increased Calreticulin Expression in Clonal Plasma Cells Is Associated with Complete Response to Melphalan and Autologous Stem Cell Transplant in Systemic Light-Chain Amyloidosis.

Ping Zhou, MD, PhD, Adam B. Olshen, PhD, Julie Teruya-Feldstein, MD, Raymond Comenzo, MD

Blood (2006) 108 (11): 3096.

https://doi.org/10.1182/blood.V108.11.3096.3096

Published: 2006

NARROW

Daratumumab Activity Is Agnostic to Fc Gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Primary Refractory or Relapsed Systemic AL Amyloidosis

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Single Agent AMD3100 Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation in Patients with Multiple Myeloma (MM).

Increased Calreticulin Expression in Clonal Plasma Cells Is Associated with Complete Response to Melphalan and Autologous Stem Cell Transplant in Systemic Light-Chain Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only